ECSP11011164A - Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica - Google Patents

Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica

Info

Publication number
ECSP11011164A
ECSP11011164A EC2011011164A ECSP11011164A ECSP11011164A EC SP11011164 A ECSP11011164 A EC SP11011164A EC 2011011164 A EC2011011164 A EC 2011011164A EC SP11011164 A ECSP11011164 A EC SP11011164A EC SP11011164 A ECSP11011164 A EC SP11011164A
Authority
EC
Ecuador
Prior art keywords
group
alkyl
nr5r6
aryl
groups
Prior art date
Application number
EC2011011164A
Other languages
English (en)
Inventor
Valerie Fossey
Jean Michel Altenburger
Geraldine Manette
Stephane Illiano
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807475A external-priority patent/FR2940652B1/fr
Priority claimed from FR0904091A external-priority patent/FR2949468B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP11011164A publication Critical patent/ECSP11011164A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a los compuestos que responden a la fórmula (I), en estado de base o de sal por adición de un ácido: (I) en la cual n es igual a 0, 1, 2, 3 o 4 ; m es igual a 0, 1 o 2 ; o es igual a 0 o 1; X representa un grupo -CH2, -CH(R')-, -NH(R')- o un heteroátomo seleccionado entre O y S, entendiéndose que R' representa un grupo alquilo(C1-C5)alquilo, alcoxi(C1-C5), -CH2-arilo, -C(O)R5 o -COOR5; R1 representa un grupo oxo, -COOR5, -W-OH o -W-NR5R6; R2 representa un átomo de H o un grupo seleccionado entre los grupos (i) alquilo(C1-C5), (ii) alcoxi(C1-C5), (iii) -COOR5, (iv) -NR5R6, (v) -C(O)-NR5R6, (vi) -SO2-NR3R4, (vii) heteroarilo eventualmente sustituidos con un grupo alquilo(C1-C5), (viii)-W-arilo, (ix) -W-heteroarilo, (x) -O-W-arilo, (xi) -O-W-heteroarilo y (xii) -O-W-NR5R6 ; entendiéndose que R3 y R4, (i) que pueden ser idénticos o diferentes, representan, independientemente uno de otro, un átomo H, un grupo alquilo(C1-C5), cicloalquilo(C3-C6), arilo, heteroarilo, -CH2-heteroarilo, alquil(C1-C5)-NR5R6, -W-OH o -W-NR5R6 ; o (ii) forman junto con el átomo de nitrógeno que los porta un grupo heterocicloalquilo eventualmente sustituido con uno o varios grupos seleccionados entre los grupos alquilo(C1-C5) y -CH2-arilo ; W es un grupo alquileno-(C1-C5), eventualmente sustituido con uno o varios grupos hidroxi; R5 y R6, que pueden ser idénticos o diferentes, representan, independientemente uno de otro, un átomo de hidrógeno o un grupo seleccionado entre los grupos alquilo(C1-C5) y los grupos cicloalquilo(C3-C6), así como su procedimiento de preparación y sus aplicaciones en terapéutica.
EC2011011164A 2008-12-29 2011-06-27 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica ECSP11011164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0807475A FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
FR0904091A FR2949468B1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ECSP11011164A true ECSP11011164A (es) 2011-07-29

Family

ID=41728182

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011164A ECSP11011164A (es) 2008-12-29 2011-06-27 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica

Country Status (34)

Country Link
US (2) US8697731B2 (es)
EP (1) EP2382215B1 (es)
JP (1) JP5865704B2 (es)
KR (1) KR101630475B1 (es)
CN (1) CN102333776B (es)
AR (1) AR074916A1 (es)
AU (1) AU2009334570B2 (es)
BR (1) BRPI0923875A2 (es)
CA (1) CA2748413A1 (es)
CO (1) CO6400145A2 (es)
CR (1) CR20110360A (es)
CY (1) CY1115635T1 (es)
DK (1) DK2382215T3 (es)
EA (1) EA019774B1 (es)
EC (1) ECSP11011164A (es)
ES (1) ES2511917T3 (es)
HK (1) HK1163679A1 (es)
IL (1) IL213790A (es)
MA (1) MA32978B1 (es)
MX (1) MX2011007061A (es)
MY (1) MY155244A (es)
NI (1) NI201100132A (es)
NZ (1) NZ593797A (es)
PA (1) PA8856101A1 (es)
PE (1) PE20120338A1 (es)
PL (1) PL2382215T3 (es)
PT (1) PT2382215E (es)
SG (1) SG172422A1 (es)
SI (1) SI2382215T1 (es)
SM (1) SMT201400157B (es)
TN (1) TN2011000308A1 (es)
TW (1) TWI441828B (es)
WO (1) WO2010076525A1 (es)
ZA (1) ZA201104785B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2511917T3 (es) 2008-12-29 2014-10-23 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
CN104321318A (zh) 2012-03-30 2015-01-28 第一三共株式会社 4-烷酰基氨基-3-吡唑啉酮衍生物
CN102731384B (zh) * 2012-07-10 2016-04-06 南开大学 一种6-甲基烟酸叔丁酯的合成方法
EP3336084B1 (en) * 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3917469A1 (de) * 1989-05-30 1990-12-06 Bayer Ag Heterocyclylpyridine
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
WO2005030121A2 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
JP5443988B2 (ja) * 2006-10-16 2014-03-19 メディシス・ファーマシューティカル・コーポレーション 治療用のピラゾリルチエノピリジン
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
BRPI0812361A2 (pt) * 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese
JP5734870B2 (ja) 2008-12-29 2015-06-17 サノフイ 2−ピリジン−2−イル−ピラゾール−3(2h)−オンの誘導体、これらの調製およびhif活性化剤としての治療用途
ES2511917T3 (es) 2008-12-29 2014-10-23 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica

Also Published As

Publication number Publication date
TN2011000308A1 (fr) 2012-12-17
EP2382215B1 (fr) 2014-07-16
NZ593797A (en) 2013-01-25
AR074916A1 (es) 2011-02-23
EA201170900A1 (ru) 2012-02-28
EP2382215A1 (fr) 2011-11-02
TW201028424A (en) 2010-08-01
PE20120338A1 (es) 2012-04-30
SMT201400157B (it) 2015-01-15
AU2009334570B2 (en) 2016-06-09
CN102333776A (zh) 2012-01-25
ZA201104785B (en) 2012-09-26
KR101630475B1 (ko) 2016-06-14
AU2009334570A1 (en) 2011-07-21
EA019774B1 (ru) 2014-06-30
MX2011007061A (es) 2011-12-16
DK2382215T3 (da) 2014-10-27
HK1163679A1 (en) 2012-09-14
SG172422A1 (en) 2011-07-28
PL2382215T3 (pl) 2015-01-30
CY1115635T1 (el) 2017-01-04
BRPI0923875A2 (pt) 2015-07-21
CA2748413A1 (fr) 2010-07-08
WO2010076525A1 (fr) 2010-07-08
MA32978B1 (fr) 2012-01-02
SI2382215T1 (sl) 2020-06-30
CO6400145A2 (es) 2012-03-15
CR20110360A (es) 2011-10-13
JP5865704B2 (ja) 2016-02-17
US20110301148A1 (en) 2011-12-08
CN102333776B (zh) 2014-05-21
NI201100132A (es) 2011-11-01
PT2382215E (pt) 2014-10-16
US8697731B2 (en) 2014-04-15
IL213790A0 (en) 2011-07-31
PA8856101A1 (es) 2010-07-27
MY155244A (en) 2015-09-30
ES2511917T3 (es) 2014-10-23
TWI441828B (zh) 2014-06-21
US20140194470A1 (en) 2014-07-10
US9359329B2 (en) 2016-06-07
IL213790A (en) 2015-09-24
JP2012513977A (ja) 2012-06-21
US20160137627A9 (en) 2016-05-19
KR20110111437A (ko) 2011-10-11

Similar Documents

Publication Publication Date Title
ECSP11011164A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
AR082004A1 (es) Compuestos de fusion de piridina
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
NI201000130A (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica.
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR088449A1 (es) Benzilindazoles sustituidos
ES2613538T3 (es) Derivados de arilamida como bloqueadores de TTX-S
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
ES2603931T3 (es) Compuestos de triazolo
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR091185A1 (es) Derivados de 1,2,4-triazol
BR112017019439A2 (pt) inibidores kv1.3 e sua aplicação médica
CO6460726A2 (es) Derivado de 5-hidroxi-pirimidin-4-carboxamida
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR077363A1 (es) DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS.
CO5650235A2 (es) Derivados de imidazol
AR054033A1 (es) Derivados de triazinas su preparacion y su aplicacion en terapeutica
AR082912A1 (es) Metodo para producir compuestos de piridazinona y un intermediario de sintesis